Medtronic Artificial Pancreas Sustains Normal Glucose 42% Of The Time
This article was originally published in The Gray Sheet
Executive Summary
Medtronic/MiniMed continues to predict that its artificial pancreas technology will reach the U.S. market in five years, based on early-stage data showing the system maintains glucose levels in the near-normal range 42% of the time